Efficacy and safety of Peginterferon alfa-2b plus Ribavirin for HCV-positive mixed cryoglobulinemia: A multicentre open-label study

Cesare Mazzaro, Giuseppe Monti, Francesco Saccardo, Anna Linda Zignego, Clodoveo Ferri, Salvatore De Vita, Armando Gabrielli, Marco Lenzi, Carlo Donada, Massimo Galli, Maurizio Pietrogrande, Gabriele Pozzato

Research output: Contribution to journalArticle

Abstract

Objective: The aim of the present study is to provide information on clinical outcome of the patients affected by HCV-positive mixed cryoglobulinemia (MC) treated with PEG-IFN and Ribavirin for 6 or 12 months according to the HCV genotype. Methods: Eighty-six patients (42 women and 44 men) were enrolled in 8 Italian centres. All the patients had MC in the active phase of the disease. The patients received Peginterferon alfa-2b 1.5 mcg/kg/once a week (QW) and daily oral Ribavirin (800/1,000/1,200) according to their body weight for 48 weeks for genotype 1 and 4 and for 24 weeks for genotypes 2 and 3. Results: In the 44 patients who underwent 12 months of therapy, 17 cases (39%) could be considered as "non-responders" and 11 relapsed, therefore only 16 patients (36%) obtained a sustained virological response. In the 42 patients who underwent six months of therapy only 7 cases (17%) could be considered as "non-responders" and 8 relapsed, therefore 27 patients (64%) obtained a sustained virological response. Purpura score dropped in both group (p-17) and only 5 cases of the group A (11%) and 5 of the group B (12%) did not show any improvement. Arthralgias showed a similar behaviour. Many patients relapsed after the end of the treatment. Conclusion: This study documents a lower response rate than that observed in the clinical trials with HCV chronic hepatitis, but the presence of comorbidities and older age should be taken into consideration. Most patients (88.5%) showed a complete and persistent recovery from clinical symptoms.

Original languageEnglish
Pages (from-to)933-941
Number of pages9
JournalClinical and Experimental Rheumatology
Volume29
Issue number6
Publication statusPublished - 2011

    Fingerprint

Keywords

  • Antiviral therapy
  • Cryoglobulinemia glomerulonephritis
  • HCV genotype
  • Hepatitis C virus
  • Mixed cryoglobulinemia

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Mazzaro, C., Monti, G., Saccardo, F., Zignego, A. L., Ferri, C., De Vita, S., Gabrielli, A., Lenzi, M., Donada, C., Galli, M., Pietrogrande, M., & Pozzato, G. (2011). Efficacy and safety of Peginterferon alfa-2b plus Ribavirin for HCV-positive mixed cryoglobulinemia: A multicentre open-label study. Clinical and Experimental Rheumatology, 29(6), 933-941.